MARLBOROUGH, Mass. -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces new worldwide data with its technology ...

Running all CardioFocus clinical projects and can support focal, large area focal, regional, and single shot catheter systems for current and future PFA requirements Demonstrated compatibility across ...

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced the first series of patients treated with the investigational OptiShot(TM ...

CardioFocus has treated the first patients in an investigational trial of OptiShot, its pulsed field ablation (PFA) system for treating paroxysmal atrial fibrillation (AF). The patients in the ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced the publication of the 12-month ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Marlborough, Mass.-based CardioFocus Inc. has made its ...

MARLBOROUGH, Mass., CardioFocus, Inc., a medical device company developing the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), the most common cardiac ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

CardioFocus, Inc., a medical device company dedicated to advancing pulsed field ablation (PFA) treatment for cardiac arrhythmias, announced major advancements across its PFA portfolio. OptiShot(TM) -- ...

OptiShot ultra-compliant balloon enables tissue contact and precise anatomic delivery of pulsed energy for treatment of atrial fibrillation in first European patients MARLBOROUGH, Mass.--(BUSINESS ...